Skip to Main Content
Phase I

TrialNet TOPPLE Study for People with Type 1 Diabetes

  • Study HIC#:2000029217
  • Last Updated:01/01/0001

TrialNet is testing the safety of a new treatment, NNC0361-0041, in adults, 18-45, with Type 1 Diabetes (T1D) diagnosed within the past 48 months. The treatment is a plasmid vector designed to transfer DNA into cells, where it can communicate with the immune system. Earlier studies in the lab show this treatment might retrain the immune system to stop its attack on insulin-producing beta cells.

While plasmids are small circular pieces of DNA, they do not change your DNA. They are currently being studied in many clinical trials for other conditions.

This study has a 12-week treatment phase, followed by 9 months of follow up.

  • Age18 years - 45 years
  • GenderBoth

Contact Us

For more information about this study, including how to volunteer, contact:

Lori Carria

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

Eligibility Criteria

Main Eligibility Requirements

  • Age 18-45
  • T1D diagnosis in past 48 months.

Principal Investigator

Sub-Investigators

For more information about this study, including how to volunteer, contact: